| Rank |
Title |
Year |
PubWeight™‹?› |
|
1
|
The cancer/testis genes: review, standardization, and commentary.
|
2004
|
4.78
|
|
2
|
Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human colorectal cancer.
|
2007
|
2.44
|
|
3
|
Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials.
|
2010
|
2.07
|
|
4
|
Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin.
|
2007
|
2.00
|
|
5
|
Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha.
|
2007
|
1.82
|
|
6
|
Depletion of CD25+ regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice.
|
2002
|
1.80
|
|
7
|
The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases.
|
2008
|
1.75
|
|
8
|
Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma.
|
2009
|
1.74
|
|
9
|
CTLA-4 blockade in tumor models: an overview of preclinical and translational research.
|
2013
|
1.71
|
|
10
|
Humoral immunity to human breast cancer: antigen definition and quantitative analysis of mRNA expression.
|
2001
|
1.69
|
|
11
|
Efficiency of recombinant human TNF in human cancer therapy.
|
2006
|
1.58
|
|
12
|
Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma.
|
2010
|
1.57
|
|
13
|
DNA methylation-dependent regulation of BORIS/CTCFL expression in ovarian cancer.
|
2007
|
1.53
|
|
14
|
Expression of the cancer/testis antigen NY-ESO-1 in primary and metastatic malignant melanoma (MM)--correlation with prognostic factors.
|
2007
|
1.46
|
|
15
|
Prognostic impact of cancer/testis antigen expression in advanced stage multiple myeloma patients.
|
2008
|
1.45
|
|
16
|
Increased frequency of regulatory T cells in peripheral blood and tumour infiltrating lymphocytes in colorectal cancer patients.
|
2007
|
1.43
|
|
17
|
Characterization of cancer stroma markers: in silico analysis of an mRNA expression database for fibroblast activation protein and endosialin.
|
2005
|
1.38
|
|
18
|
T cell immunomonitoring and tumor responses in patients immunized with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein.
|
2007
|
1.34
|
|
19
|
Expression of cancer/testis (CT) antigens MAGE-A1, MAGE-A3, MAGE-A4, CT-7, and NY-ESO-1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of disease.
|
2003
|
1.32
|
|
20
|
Cancer/testis (CT) antigens - a new link between gametogenesis and cancer.
|
2001
|
1.31
|
|
21
|
Monoclonal antibodies in cancer therapy.
|
2012
|
1.31
|
|
22
|
Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA.
|
2004
|
1.29
|
|
23
|
LUD 00-009: phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancer.
|
2007
|
1.28
|
|
24
|
Identification of CT46/HORMAD1, an immunogenic cancer/testis antigen encoding a putative meiosis-related protein.
|
2005
|
1.26
|
|
25
|
NKG2D ligands as therapeutic targets.
|
2013
|
1.26
|
|
26
|
Dysregulation in immune functions is reflected in tumor cell cytotoxicity by peripheral blood mononuclear cells from head and neck squamous cell carcinoma patients.
|
2008
|
1.26
|
|
27
|
PLAC1, a trophoblast-specific cell surface protein, is expressed in a range of human tumors and elicits spontaneous antibody responses.
|
2007
|
1.21
|
|
28
|
Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human glioma.
|
2007
|
1.20
|
|
29
|
Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer.
|
2003
|
1.19
|
|
30
|
Database of T cell-defined human tumor antigens: the 2013 update.
|
2013
|
1.19
|
|
31
|
Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human bladder cancer.
|
2007
|
1.19
|
|
32
|
Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma.
|
2013
|
1.17
|
|
33
|
The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand.
|
2004
|
1.15
|
|
34
|
Rapid destruction of the tumor microenvironment by CTLs recognizing cancer-specific antigens cross-presented by stromal cells.
|
2005
|
1.15
|
|
35
|
The localization and density of immune cells in primary tumors of human metastatic colorectal cancer shows an association with response to chemotherapy.
|
2009
|
1.14
|
|
36
|
Digital expression profiles of human endogenous retroviral families in normal and cancerous tissues.
|
2004
|
1.13
|
|
37
|
Immunogenic peptides generated by frameshift mutations in DNA mismatch repair-deficient cancer cells.
|
2004
|
1.12
|
|
38
|
Generation of monoclonal antibodies to cancer/testis (CT) antigen CT10/MAGE-C2.
|
2006
|
1.10
|
|
39
|
Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma.
|
2009
|
1.09
|
|
40
|
Cancer vaccines: an overview.
|
2008
|
1.09
|
|
41
|
Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in head and neck cancers.
|
2008
|
1.09
|
|
42
|
Two phase I studies of low dose recombinant human IL-12 with Melan-A and influenza peptides in subjects with advanced malignant melanoma.
|
2003
|
1.08
|
|
43
|
Mapping and binding analysis of peptides derived from the tumor-associated antigen survivin for eight HLA alleles.
|
2005
|
1.07
|
|
44
|
CD44+ cancer cells express higher levels of the anti-apoptotic protein Bcl-2 in breast tumours.
|
2009
|
1.06
|
|
45
|
Listeria-based vaccines can overcome tolerance by expanding low avidity CD8+ T cells capable of eradicating a solid tumor in a transgenic mouse model of cancer.
|
2007
|
1.06
|
|
46
|
Translating basic mechanisms of IgG effector activity into next generation cancer therapies.
|
2012
|
1.05
|
|
47
|
Upregulation of MICA on high-grade invasive operable breast carcinoma.
|
2007
|
1.04
|
|
48
|
Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma.
|
2006
|
1.04
|
|
49
|
Cancer/testis antigen expression and autologous humoral immunity to NY-ESO-1 in gastric cancer.
|
2004
|
1.04
|
|
50
|
Cancer is a somatic cell pregnancy.
|
2007
|
1.02
|